Gnubiotics presents novel data on glycan based microbiome modulation at the 41st European Society of Clinical Nutrition and Metabolism (ESPEN) Congress in Krakow Poland, Saturday August 31 – September 3rd 2019.
Poster MON-PO568 “Selective in vitro activity of Microbiota Accessible Carbohydrates on key bacteria from the gut microbiome” Presented at41st European Society of Clinical Nutrition and Metabolism (ESPEN) Congress in Krakow Poland, Saturday August 31 – September 3rd 2019.
This data includes the growth stimulation of Akkermansia Muciniphila a microbe that has been correlated with better response to PD-1 based immunotherapy.
Selective in vitro activity of Microbiota Accessible Carbohydrates on key bacteria from gut microbiome [MON-PO568
Sara Vidal1*, Yong Miao1, Philippe Steenhout1, Yemi Adesokan1
1 Gnubiotics Science SA, Microbiome Research, StartLab / Biopôle, Bat SE-B, Route de la Corniche 5, CH1066, Epalinges, Switzerland.
* Corresponding author: email@example.com
Human Milk Oligosaccharides (HMOs) are unconjugated complex carbohydrates abundant in human milk. HMOs selectively serve as a source of energy for desired bacteria in the infant gut modulating mucosal barrier function and promoting immunological responses. We have developed an oligosaccharide-based formulation containing up to 130 Microbiota Accessible Carbohydrates (MACs) mimicking the natural diversity and complexity of HMOs. Our aim was to investigate the ability of key bacteria from the gut to use the formulation GMX in vitro.
All the tested strains were able to grow better in liquid minimal medium (MM) with GMX in comparison with MM without supplementation. In Bifidobacterium bifidum, the maximum growth was reached after 96h (OD = 0.704). However, in B. animalis, B. breve and Lactobacillus acidophilus it was reached after 24h (OD = 0.315, OD = 0.607 and OD = 0.713, respectively). The bacterial species exhibiting more growth after 24h were Akkermansia muciniphila (OD = 1.292) and Bacteroides thetaiotaomicron (OD = 1.11).
MAC formulation GMX with a functional diversity similar to HMOs has the capacity to stimulate important components of the gut microbiota in vitro. Our MAC formulation could have the potential to a serve as a source of energy and nutrients for beneficial intestinal bacteria helping to restore a healthy microbiota in patients with dysbiosis such as in inflammatory bowel conditions. Finally, key bacteria presented in this poster have been shown to play a role in positive response against cancer immunotherapy, thus opening new possible indictions for GMX.
B. bifidum ATCC 11863, B. animalis subsp. lactis DSMZ 10140, B. breve ATCC 15700, L. acidophilus ATCC 13651. A. muciniphila ATCCBAA835 and B. thetaiotaomicron ATCC 29148 were cultivated in liquid minimal medium (MM) supplemented with glucose, MM Supplemented with the formulation GMX and MM without supplementation. Cultures were performed in 96-well plates in triplicate in anaerobiosis at 37 C and bacterial growth was measured by optical density (OD) at 600nm after 24h, 48h, 72h and 96h.